Kerwyn Huang

This session highlights thecurrent FDA approved microbiome therapeutics and their applications and the exciting avenues being pursued for the next generation of microbiome therapeutics using gene editing and synthetic microbial communities…

BACKGROUND: Recurrent _Clostridioides difficile _infection (rCDI) is a debilitating disease associated with significant healthcare burden and low quality of life. The greatest risk factor for rCDI is a history of recurrence, although older age (≥65 years) and comorbidities also increase risk…